ACRO Biomedical: A Pioneer in Regenerative Medicine

Developing World-Class Products, Winning the National Innovation Award for the Innovative Application of Acellular Dermal Matrix (Micro-Particle) in Medical Devices

ACRO Biomedical (Stock Code: 6748), a leading innovator in regenerative medicine, has consistently achieved major breakthroughs in biomedical materials and human organ tissue engineering. Its cutting-edge technologies have earned it the prestigious National Innovation Award three times:

• In 2017, ACRO won the 14th National Innovation Award for its Artificial Corneal Stroma.

• In 2021, it secured the 18th National Innovation Award for its Innovative Organ Regeneration Technology.

• Now, in 2024, ACRO has been honored with the 21st National Innovation Award for the Innovative Application of Acellular Dermal Matrix (Micro-Particle) in Medical Devices.

Each recognition serves as a testament to the evolution of regenerative medicine in Taiwan and reinforces ACRO Biomedical’s position as a rising star in the field.

Leading the Future of Regenerative Medicine

Dr. Dar-Jen Hsieh, Chairman of ACRO Biomedical, emphasized that regenerative medicine is a rapidly growing global industry that demands continuous investment in R&D and clinical trials in collaboration with medical institutions worldwide.

All ACRO Biomedical products undergo rigorous regulatory evaluations and have been granted marketing approvals by Taiwan’s Ministry of Health and Welfare (TFDA), ensuring safety and reliability for medical professionals and patients alike.

Innovative Technologies Creating World-Class Products

Since its inception, ACRO Biomedical has been dedicated to developing world-class products through its cutting-edge supercritical CO₂ platform technology for regenerative medicine applications. The company’s relentless innovation has yielded 93 global patents and 48 medical device approvals worldwide. Its diverse product portfolio spans wound care, orthopedics, dentistry, ophthalmology, and medical aesthetics, solidifying its role as a leader in Taiwan’s regenerative medicine industry.

Global Expansion and Regulatory Milestones

ACRO Biomedical's medical devices have been gaining increasing industry attention. In 2024, the company achieved several key milestones:

• In April, three regenerative medical devices—

  • ABCcolla® Hemostatic Collagen Matrix

  • Hemostatic ADM Scaffold

  • Hemostatic ADM Paste
    received Class III medical device approval from Taiwan’s Ministry of Health and Welfare (TFDA).

• In October, ABCcolla® Collagen ADM Scaffold obtained U.S. FDA 510(k) clearance for commercialization in the United States.

• In December, ACRO Biomedical was awarded the 21st National Innovation Award for the Innovative Application of Acellular Dermal Matrix (Micro-Particle) in Medical Devices.

With an aggressive global expansion strategy, ACRO is rapidly advancing its international regulatory approvals, laying a new blueprint for global market entry.

A Benchmark in the Biomedical Industry

Dr. Hsieh highlighted the prestige of the National Innovation Award, likening it to “the Oscars of the biomedical industry”. Winning the 21st National Innovation Award / Corporate Innovation Award demonstrates that ACRO’s commitment to advancing human organ and tissue regeneration is gaining recognition across the biomedical sector.

“We continue to turn the impossible into possible.”

 

URL:ACRO Biomedical: A Pioneer in Regenerative Medicine